Burjeel Holdings PLC, a prominent healthcare provider in the UAE, reported a robust 14.1% increase in third-quarter revenue for 2024, driven by rising patient footfall and improved service yields. Total revenue for the first nine months reached Dh3.7 billion, marking an 11.7% year-on-year increase with 4.8 million patient visits, underscoring strong demand across its facilities, including Burjeel Medical City, Burjeel Specialty Hospital in Sharjah, Medeor Hospital Dubai, and Burjeel Royal Hospital Asharej.
Significant growth was observed across Burjeel’s key service areas. Oncology revenue saw a notable increase of 50%, accounting for 20% of the company’s incremental revenue growth. Inpatient visits surged by 13.3%, pushing bed occupancy rates to 66% with over 60,800 surgeries completed, a 13% rise year-on-year. Outpatient numbers rose by 7.9%, fueled by expansions and enhanced cross-referral processes within the Group’s network.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 5.1% in Q3 to Dh273 million, despite the impact of increased costs due to new assets and marketing efforts targeting the international patient program. Excluding these costs, adjusted Q3 EBITDA rose by 11.4% to Dh290 million, achieving a 22% margin. The Group’s net profit before taxes also grew by 9.8% to Dh151 million, reflecting enhanced operational performance and optimized depreciation.
Burjeel has been advancing its footprint in the UAE and Saudi Arabia through targeted investments. In Saudi Arabia, the company opened 11 new PhysioTherabia centers in Q3, bringing its total to 28 branches, aligning with Saudi Vision 2030 to expand wellness services. In the UAE, Burjeel launched nine new community clinics designed to serve 300,000 outpatient visits annually, enhancing access to primary care and supporting cross-referrals to its hospitals. Additionally, Burjeel inaugurated the UAE’s largest fertility center, extending reproductive health services from conception to delivery.
These expansions, combined with strategic partnerships, reinforce Burjeel’s goal of offering advanced healthcare. A collaboration with Abu Dhabi Stem Cells Center marks one such initiative, focusing on bone marrow transplants and cellular therapies to treat complex conditions like blood cancers, genetic disorders, and autoimmune diseases.
In response to its performance, Burjeel Holdings CEO John Sunil highlighted the Group’s ongoing commitment to regional expansion and super-specialty care. “Our 14% revenue growth in the third quarter, driven by a 12% increase in patient footfall, reflects Burjeel’s strategic investments in high-growth services,” Sunil said. “We are aligning closely with the UAE’s healthcare strategy through community-based primary care clinics, while in Saudi Arabia, our expanding PhysioTherabia network supports Vision 2030 goals.”
Looking ahead, Burjeel Holdings remains optimistic about future growth driven by rising healthcare demand in the region. The Group has refined its year-end outlook to reflect its accelerating network expansion and super-specialty service investments, particularly in high-yield areas such as oncology. Burjeel anticipates sustained growth in patient numbers and market share, bolstered by ongoing investments that position it to leverage favorable macroeconomic trends in the UAE and Saudi Arabia.
